SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Harrouseau JL,Greil R,Kloke O; ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma. Ann Oncol. 2005; 16( suppl 1): i45i47.
  • 2
    Imrie K,Esmail R,Meyer RM; Members of the Hematology Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative. The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. Ann Intern Med. 2002; 136: 619629.
  • 3
    Shimizu K; Japan Myeloma Study Group. Guidelines for the diagnosis and management of multiple myeloma by the Japan Myeloma Study Group [in Japanese]. Rinsho Ketsueki. 2005; 46: 424432.
  • 4
    Smith A,Wisloff F,Samson D; UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006; 132: 410451.
  • 5
    Zelenetz AD,Advani RH,Buadi F, et al. Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006; 4: 258310.
  • 6
    Hoppe RT,Advani RH,Bierman PJ,Bloomfield CD,Buadi F,Djulgegovic B, et al. Hodgkin's disease/lymphoma: Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006; 4: 210230.
  • 7
    Jost LM,Stahel RA; ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Hodgkin's disease. Ann Oncol. 2005; 16( suppl 1): i54i55.
  • 8
    Center for International Blood and Marrow Transplantation Research (CIBMTR). Current Use and Outcome of Hematopoietic Stem Cell Transplantation 2005. Available at: http://campus.mcw.edu/AngelUploads/Content/CS_IBMTR2/_assoc/ECCBED0AF0A4492BB667FB6227DC7C06/summaryslides2005_Pt1_files/frame.htm [Accessed October 16, 2006].
  • 9
    Bennett CL,Armitage JL,Armitage GO, et al. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991. J Clin Oncol. 1995; 13: 969973.
  • 10
    Beard SM,Wall L,Gaffney L,Sampson F. Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy. Pharmacoeconomics. 2004; 22: 207224.
  • 11
    Sweetenham JW. Economics of stem cell transplantation for lymphoma: counting the cost of living. Br J Cancer. 2000; 82: 46.
  • 12
    Freeman M,Vose J,Bennett C, et al. Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska medical center 1989 to 1995. Bone Marrow Transplant. 1999; 24: 679684.
  • 13
    Waters TM,Bennett CL,Pajeau TS, et al. Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: what do we know? Bone Marrow Transplant. 1998; 21: 641650.
  • 14
    Mishra V,Andresen S,Brinch L, et al. Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study. Bone Marrow Transplant. 2005; 35: 11491153.
  • 15
    Kouroukis CT,O'Brien BJ,Benger A, et al. Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma. Leuk Lymphoma. 2003; 44: 2937.
  • 16
    Mishra V,Vaaler S,Brinch L. Cost analysis of autologous peripheral blood stem cell transplantation for multiple myeloma. Clin Lab Haematol. 2003; 25: 179184.
  • 17
    Sampson FC,Beard SM,Scott F,Vandenberghe E. Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma. Br J Haematol. 2001; 113: 10151019.
  • 18
    Lee SJ,Klar N,Weeks JC,Antin JH. Predicting costs of stem-cell transplantation. J Clin Oncol. 2000; 18: 6471.
  • 19
    Esperou H,Brunot A,Roudot-Thoraval F, et al. Predicting the costs of allogeneic sibling stem-cell transplantation: Results from a prospective, multicenter, French study. Transplantation. 2004; 77: 18541858.
  • 20
    Healthcare Cost and Utilization Project (HCUP). HCUP Nationwide Inpatient Sample (NIS). Available at: www.hcup-us.ahrq.gov/nisoverview.jsp
  • 21
    United States. Health Care Financing Administration. ICD-9-CM: International Classification of Diseases, Clinical Modification. Vol 91-1260. 4th, 9th revised ed. Washington, DC: US Department of Health and Human Services, Public Health Service, Health Care Financing Administration; US Government Printing Office; 1991.
  • 22
    Charlson ME,Pompei P,Ales KL,MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987; 40: 373383.
  • 23
    Romano PS,Roos LL,Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993; 46: 10751079; discussion 1081–1090.
  • 24
    Centers for Medicare & Medicaid Services (CMS), HHS. Medicare program; changes to the hospital inpatient prospective payment systems and rates and costs of graduate medical education: Fiscal year 2002 rates; provisions of the balanced budget refinement act of 1999; and provisions of the Medicare, Medicaid, and SCHIP benefits improvement and protection act of 2000. Final rules. Fed Regist. 2001; 66: 3982740102.
  • 25
    US Department of Labor Bureau of Labor Statistics. July 2003 Medicare cost-to-charge reimbursement. Washington, DC: US Department of Labor; 2004.
  • 26
    Thompson SG,Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ. 2000; 320: 11971200.
  • 27
    Jemal A,Siegel R,Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106130.
  • 28
    Buchali A,Feyer P,Groll J,Massenkeil G,Arnold R,Budach V. Immediate toxicity during fractionated total body irradiation as conditioning for bone marrow transplantation. Radiother Oncol. 2000; 54: 157162.
  • 29
    Gutierrez-Delgado F,Holmberg L,Hooper H, et al. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant. 2003; 32: 279285.
  • 30
    Gutierrez-Delgado F,Maloney DG,Press OW, et al. Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens. Bone Marrow Transplant. 2001; 28: 455461.
  • 31
    Stiff PJ,Unger JM,Forman SJ, et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant. 2003; 9: 529539.
  • 32
    Newhouse J. Medical care costs: how much welfare loss? J Econ Perspectives. 1992; 6: 321.
  • 33
    Iezzoni LI. Risk Adjustment for Measuring Health Care Outcomes. 3rd ed. Chicago. Health Administration Press; 2003.